KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance

被引：0
|
作者：
Song Zheng
Ke-er Huang
Yue-long Pan
Yao Zhou
Song-dan Pan
Xin Li
Jing Jia
Xiao-liang Zheng
De-you Tao
机构：
[1] The First People’s Hospital of Hangzhou,Department of Oncology, Hangzhou Cancer Hospital
[2] Zhejiang University,Department of Emergency, Second Affiliated Hospital, School of Medicine
[3] Zhejiang Academy of Medical Sciences,Department of Oncology
[4] Taizhou Hospital of Zhejiang Province,undefined
来源：
Gastric Cancer | 2015年 / 18卷
关键词：
Gastrointestinal stromal tumor; KIT; BRAF; Rhabdomyosarcomatous differentiation; Imatinib resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：796 / 802
页数：6
相关论文
共 50 条
  • [31] KIT and PDGFRA Mutations in Gastrointestinal Stromal Tumors in India
    Shetty, O.
    Pai, T.
    Gurav, M.
    Bal, M.
    Ramadwar, M.
    Arora, I.
    Kurani, H.
    Rumde, R.
    Dhanavade, D.
    Ostwal, V.
    Desai, S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 826 - 827
  • [32] Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
    Edris, Badreddin
    Willingham, Stephen
    Weiskopf, Kipp
    Volkmer, Anne K.
    Volkmer, Jens-Peter
    Muehlenberg, Thomas
    Weissman, Irving L.
    van de Rijn, Matt
    ONCOIMMUNOLOGY, 2013, 2 (06):
  • [33] A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
    Chen, LL
    Trent, JC
    Wu, EF
    Fuller, GN
    Ramdas, L
    Zhang, W
    Raymond, AK
    Prieto, VG
    Oyedeji, CO
    Hunt, KK
    Pollock, RE
    Feig, BW
    Hayes, KJ
    Choi, H
    Macapinlac, HA
    Hittelman, W
    Velasco, MA
    Patel, S
    Burgess, MA
    Benjamin, RS
    Frazier, ML
    CANCER RESEARCH, 2004, 64 (17) : 5913 - 5919
  • [34] Molecular Mechanisms of Resistance to Imatinib or Sunitinib in KIT Mutants from Patients with Gastrointestinal Stromal Tumors
    Wu, Joe C.
    FASEB JOURNAL, 2010, 24
  • [35] Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor
    Zheng, Song
    Pan, Yue-Long
    Tao, De-You
    Wang, Jiao-Li
    Huang, Ke-Er
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (06) : 760 - 763
  • [36] Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors
    Jasek, Karin
    Buzalkova, Veronika
    Minarik, Gabriel
    Stanclova, Andrea
    Szepe, Peter
    Plank, Lukas
    Lasabova, Zora
    VIRCHOWS ARCHIV, 2017, 470 (01) : 29 - 36
  • [37] Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors
    Karin Jasek
    Veronika Buzalkova
    Gabriel Minarik
    Andrea Stanclova
    Peter Szepe
    Lukas Plank
    Zora Lasabova
    Virchows Archiv, 2017, 470 : 29 - 36
  • [38] Residual and Recurrent Gastrointestinal Stromal Tumors With KIT Mutations: Findings at First Follow-Up CT After Imatinib Treatment
    Choi, Dongil
    Yoo, Eun Young
    Kim, Kyoung-Mee
    Sohn, Tae Sung
    Lee, Won Jae
    Lee, Ji Young
    Chang, Ilsoo
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 193 (02) : W100 - W105
  • [39] Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor
    Nishida, Toshirou
    Kanda, Tatsuo
    Nishitani, Akiko
    Takahashi, Tsuyoshi
    Nakajima, Kiyokazu
    Ishikawa, Takashi
    Hirota, Seiichi
    CANCER SCIENCE, 2008, 99 (04): : 799 - 804
  • [40] Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
    Agaram, Narasimhan P.
    Wong, Grace C.
    Guo, Tianhua
    Maki, Robert G.
    Singer, Samuel
    DeMatteo, Ronald P.
    Besmer, Peter
    Antonescu, Cristina R.
    GENES CHROMOSOMES & CANCER, 2008, 47 (10): : 853 - 859
12345